Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;46(9):4593-4599.
doi: 10.1007/s10072-025-08290-9. Epub 2025 Jun 9.

Frequency of anti-GQ1b IgG antibody in Miller Fisher syndrome: a Chinese single center study

Pengfei Shao  1   2   3   4   5 , Wenhui Wu  6 , Xin Zhang  1   2   3   4   5 , Haifeng Chen  1   2   3   4   5 , Yun Xu  7   8   9   10   11 , Qing Ye  12   13   14   15   16
Affiliations

Frequency of anti-GQ1b IgG antibody in Miller Fisher syndrome: a Chinese single center study

Pengfei Shao et al. Neurol Sci. 2025 Sep.

Abstract

Background: The anti-GQ1b IgG antibody has been traditionally regarded as a sensitive marker for Miller Fisher syndrome (MFS). Nevertheless, its prevalence might vary across regions and could be affected by the coronavirus disease 2019 (COVID-19) pandemic. This retrospective study was designed to evaluate the positivity rate of the anti-GQ1b IgG antibody among MFS patients admitted to a single Chinese center and to examine the influence of the COVID-19 pandemic thereon.

Methods: We retrospectively analyzed the medical records of patients diagnosed with MFS and admitted to our hospital from January 2018 to March 2024. Anti-ganglioside antibodies were tested in acute-phase serum samples using enzyme-linked immunosorbent assay (ELISA) or immune-dot assays.

Results: Of the 72 patients admitted for MFS, 51 were tested for ganglioside antibodies. Only 9 (17.65%) of the tested patients were found to have the anti-GQ1b IgG antibody. The positivity rate of the antibody was comparable between patients with the complete form of MFS and those with the incomplete form (17.39% vs. 17.86%, P = 0.965). Additionally, the positivity rate was significantly lower during and after the COVID-19 pandemic compared to before the pandemic (8.33% vs. 40.00%, P = 0.007).

Conclusions: The anti-GQ1b IgG antibody is infrequently detected in MFS patients admitted to our center, especially during and after the COVID-19 pandemic. Future prospective multicenter investigations are expected to contribute significantly to the further clarification of the prevalence of anti-GQ1b IgG antibody in MFS patients across various regions of China.

Keywords: China; Coronavirus disease 2019; Miller Fisher syndrome; anti-GQ1b IgG antibody.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no conflict of interest.

References

    1. Chiba A, Kusunoki S, Shimizu T et al (1992) Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome [J]. Ann Neurol 31(6):677–679 - PubMed
    1. ITO M, Kuwabara S, Odaka M et al (2008) Bickerstaff’s brainstem encephalitis and fisher syndrome form a continuous spectrum: clinical analysis of 581 cases [J]. J Neurol 255(5):674–682 - PubMed
    1. JUNG JH, OH E H, SHIN JH et al (2019) Atypical clinical manifestations of Miller Fisher syndrome [J]. Neurol Sci 40(1):67–73 - PubMed
    1. Schwerer B, Neisser A, Bernheimer H (1999) Distinct Immunoglobulin class and Immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection [J]. Infect Immun 67(5):2414–2420 - PubMed - PMC
    1. San-Juan O D, Martinez-Herrera J F, Garcia JM et al (2009) Miller Fisher syndrome: 10 years’ experience in a third-level center [J]. Eur Neurol 62(3):149–154

Supplementary concepts

LinkOut - more resources